Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02616796|
Recruitment Status : Unknown
Verified April 2019 by Scott Hall, Stanford University.
Recruitment status was: Recruiting
First Posted : November 30, 2015
Last Update Posted : May 1, 2019
|Condition or disease||Intervention/treatment||Phase|
|Fragile X Syndrome Intellectual Disability||Behavioral: Social gaze training||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
Experimental: Social gaze training
Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
Behavioral: Social gaze training
Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
No Intervention: No Training
Appropriate social gaze behavior will not be reinforced.
- Percentage of social gaze aversion recorded during the social challenge [ Time Frame: 3 days ]
- Heart rate recorded during the social challenge [ Time Frame: 3 days ]
- Total t-score on the Social Responsiveness Scale (SRS) [ Time Frame: 4 weeks ]
- Verbal responses and pauses in conversation observed during the social challenge [ Time Frame: 3 days ]
- Fractional Amplitude of Low Frequency fluctuations (fALLF) measured in the insular cortex [ Time Frame: 3 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02616796
|Contact: Scott S Hall, PhDemail@example.com|
|United States, California|
|Stanford University School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Scott S Hall, PhD 650-498-4799 firstname.lastname@example.org|
|Principal Investigator: Scott S Hall, PhD|